Skip to main content
Top
Published in: Journal of Clinical Immunology 6/2006

01-11-2006

Double Reactivity Against Actin and α-Actinin Defines a Severe Form of Autoimmune Hepatitis Type 1

Authors: GUÉGUEN PAUL, DALEKOS GEORGIOS, NOUSBAUM JEAN-BAPTISTE, ZACHOU KALLIOPI, PUTTERMAN CHAIM, YOUINOU PIERRE, RENAUDINEAU YVES

Published in: Journal of Clinical Immunology | Issue 6/2006

Login to get access

Abstract

Anti-filamentous actin antibodies characterize autoimmune hepatitis type 1 (AIH-1). Recently, the binding domain of α-actinin on actin was shown to be a predominant epitope. To test this reactivity, an anti-α-actinin enzyme-linked immunosorbent assay was developed, and positivity confirmed by Western blot. Anti-α-actinin antibody was found in 21/50 (42%) of AIH-1 patients, compared with 52/401 (12.9%) of liver disease control patients, and with 6/200 (6%) of blood donors. Anti-filamentous and anti-α-actinin activities were found specifically together in 66% of anti-filamentous-positive AIH-1 patients. This combination of specificities reflected clinical and histological disease activity, short duration and absence of treatment. Finally, using an actin-α-actinin complex assay, the binding of anti-filamentous actin to α-actinin-binding domain on actin was demonstrated, as well as that of anti-α-actinin on the actin-binding domain of α-actinin. Thus, the frequent combination of anti-filamentous and anti-α-actinin antibodies seems to be the hallmark of activity in AIH-1.
Footnotes
1
The IAHG score includes many parameters (sex, IgG increase, positivity for autoantibodies) including biopsy findings.
 
Literature
1.
go back to reference Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M, et al.: International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938, 1999PubMedCrossRef Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M, et al.: International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31:929–938, 1999PubMedCrossRef
2.
go back to reference Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB: Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 59:280–284, 2006PubMedCrossRef Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB: Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 59:280–284, 2006PubMedCrossRef
3.
go back to reference Czaja AJ, Morshed SA, Parveen S, Nishioka M: Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 26:567–572, 1997PubMedCrossRef Czaja AJ, Morshed SA, Parveen S, Nishioka M: Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology 26:567–572, 1997PubMedCrossRef
4.
go back to reference Zachou K, Rigopoulou E, Dalekos GN: Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 1:2, 2004PubMedCrossRef Zachou K, Rigopoulou E, Dalekos GN: Autoantibodies and autoantigens in autoimmune hepatitis: Important tools in clinical practice and to study pathogenesis of the disease. J Autoimmune Dis 1:2, 2004PubMedCrossRef
5.
go back to reference Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D: Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 36:658–664, 2002CrossRef Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, Portmann B, Underhill J, Durr R, Mieli-Vergani G, Vergani D: Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 36:658–664, 2002CrossRef
6.
go back to reference Liaskos C, Bogdanos PD, Davies ET, Dalekos GN: Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol, in press Liaskos C, Bogdanos PD, Davies ET, Dalekos GN: Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis. J Clin Pathol, in press
7.
go back to reference Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB: Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24:1068–1073, 1996PubMedCrossRef Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB: Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 24:1068–1073, 1996PubMedCrossRef
8.
go back to reference Jesaitis AJ, Gizachew D, Dratz EA, Siemsen DW, Stone KC, Burrit JB: Actin surface structure revealed by antibody imprints: Evaluation of phage-display analysis of anti-actin antibodies. Protein Sci 8:760–770, 1999PubMed Jesaitis AJ, Gizachew D, Dratz EA, Siemsen DW, Stone KC, Burrit JB: Actin surface structure revealed by antibody imprints: Evaluation of phage-display analysis of anti-actin antibodies. Protein Sci 8:760–770, 1999PubMed
9.
go back to reference Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P: Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun 20:333–344, 2003PubMedCrossRef Zamanou A, Samiotaki M, Panayotou G, Margaritis L, Lymberi P: Fine specificity and subclasses of IgG anti-actin autoantibodies differ in health and disease. J Autoimmun 20:333–344, 2003PubMedCrossRef
10.
go back to reference McGough A, Way M, DeRosier D: Determination of the alpha-actinin-binding site on actin filaments by cryoelectron microscopy and image analysis. J Cell Biol 126:433–443, 1994PubMedCrossRef McGough A, Way M, DeRosier D: Determination of the alpha-actinin-binding site on actin filaments by cryoelectron microscopy and image analysis. J Cell Biol 126:433–443, 1994PubMedCrossRef
11.
go back to reference Girard D, Senecal JL: Anti-microfilament IgG antibodies in normal adults and in patients with autoimmune diseases: Immunofluorescence and immunoblotting analysis of 201 subjects reveals polyreactivity with microfilament-associated proteins. Clin Immunol Immunopathol 74:193–201, 1995PubMedCrossRef Girard D, Senecal JL: Anti-microfilament IgG antibodies in normal adults and in patients with autoimmune diseases: Immunofluorescence and immunoblotting analysis of 201 subjects reveals polyreactivity with microfilament-associated proteins. Clin Immunol Immunopathol 74:193–201, 1995PubMedCrossRef
12.
go back to reference Otey CA, Carpen O: α-Actinin revisited: A fresh look at an old player. Cell Motil Cytoskeleton 58:104–111, 2004PubMedCrossRef Otey CA, Carpen O: α-Actinin revisited: A fresh look at an old player. Cell Motil Cytoskeleton 58:104–111, 2004PubMedCrossRef
13.
go back to reference Chan Y, Tong HQ, Beggs AH, Kunkel LM: Human skeletal muscle-specific alpha-actinin-2 and -3 isoforms from homodimers and heterodimers in vitro and in vivo. Biochem Biophys Res Commun 248:134–139, 1998PubMedCrossRef Chan Y, Tong HQ, Beggs AH, Kunkel LM: Human skeletal muscle-specific alpha-actinin-2 and -3 isoforms from homodimers and heterodimers in vitro and in vivo. Biochem Biophys Res Commun 248:134–139, 1998PubMedCrossRef
14.
go back to reference Mills M, Yang N, Weinberger R, Vander Woude DL, Beggs AH, Easteal S, North K: Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: Implications for the evolution of functional redundancy. Hum Mol Genet 10:1335–1346, 2001PubMedCrossRef Mills M, Yang N, Weinberger R, Vander Woude DL, Beggs AH, Easteal S, North K: Differential expression of the actin-binding proteins, alpha-actinin-2 and -3, in different species: Implications for the evolution of functional redundancy. Hum Mol Genet 10:1335–1346, 2001PubMedCrossRef
15.
go back to reference Lan S, Wang H, Jiang H, Mao H, Liu X, Zhang X, Hu Y, Xiang L, Yuan Z: Direct interaction between alpha-actinin and hepatitis C virus NS5B. FEBS Lett 554:289–294, 2003PubMedCrossRef Lan S, Wang H, Jiang H, Mao H, Liu X, Zhang X, Hu Y, Xiang L, Yuan Z: Direct interaction between alpha-actinin and hepatitis C virus NS5B. FEBS Lett 554:289–294, 2003PubMedCrossRef
16.
go back to reference Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Guéguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P: Association with α-actinin-binding anti-dsDNA antibody with lupus nephritis. Arthritis Rheum 54:2523–2532, 2006PubMedCrossRef Renaudineau Y, Croquefer S, Jousse S, Renaudineau E, Devauchelle V, Guéguen P, Hanrotel C, Gilburd B, Saraux A, Shoenfeld Y, Putterman C, Youinou P: Association with α-actinin-binding anti-dsDNA antibody with lupus nephritis. Arthritis Rheum 54:2523–2532, 2006PubMedCrossRef
17.
go back to reference Kyriakou D, Alexandrakis M, Zachou K, Passam F, Stathakis N, Dalekos GN: Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 39:679–685, 2003PubMedCrossRef Kyriakou D, Alexandrakis M, Zachou K, Passam F, Stathakis N, Dalekos GN: Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 39:679–685, 2003PubMedCrossRef
18.
go back to reference Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, Papamihali R, Dalekos GN: Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 24:251–260, 2005PubMedCrossRef Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, Papamihali R, Dalekos GN: Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 24:251–260, 2005PubMedCrossRef
19.
go back to reference Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA: Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum 50:866–870, 2004PubMedCrossRef Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA: Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum 50:866–870, 2004PubMedCrossRef
20.
go back to reference Croquefer S, Renaudineau Y, Jousse S, Guéguen P, Ansart S, Saraux A, Youinou P: The anti-alpha-actinin test completes anti-DNA determination in systemic lupus erythematosus. Ann N Y Acad Sci 1050:170–175, 2005PubMedCrossRef Croquefer S, Renaudineau Y, Jousse S, Guéguen P, Ansart S, Saraux A, Youinou P: The anti-alpha-actinin test completes anti-DNA determination in systemic lupus erythematosus. Ann N Y Acad Sci 1050:170–175, 2005PubMedCrossRef
21.
go back to reference Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y: Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett 48:129–132, 1995PubMedCrossRef Leibovitch L, George J, Levi Y, Bakimer R, Shoenfeld Y: Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett 48:129–132, 1995PubMedCrossRef
22.
go back to reference Dalekos GN, Makri E, Loges S, Obermayer-Straub P, Zachou K, Tsikrikas T, Schmidt E, Papadamou G, Manns MP: Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 14:35–42, 2002PubMedCrossRef Dalekos GN, Makri E, Loges S, Obermayer-Straub P, Zachou K, Tsikrikas T, Schmidt E, Papadamou G, Manns MP: Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 14:35–42, 2002PubMedCrossRef
23.
go back to reference Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP: Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C under α-interferon treatment. J Hepatol 30:366–375, 1999PubMedCrossRef Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP: Epitope mapping of cytochrome P450 2D6 autoantigen in patients with chronic hepatitis C under α-interferon treatment. J Hepatol 30:366–375, 1999PubMedCrossRef
24.
go back to reference Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 29:403–410, 1976PubMed Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, Groeschel-Stewart U. Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 29:403–410, 1976PubMed
25.
go back to reference Vergani D, Alvarez F, Bianchi FB, Cançado ELR, Mackay IR, Manns MP, Nishioka M, Penner E: Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677–683, 2004PubMedCrossRef Vergani D, Alvarez F, Bianchi FB, Cançado ELR, Mackay IR, Manns MP, Nishioka M, Penner E: Liver autoimmune serology: A consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 41:677–683, 2004PubMedCrossRef
26.
go back to reference Czaja AJ: Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 30:394–401, 1999PubMedCrossRef Czaja AJ: Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 30:394–401, 1999PubMedCrossRef
27.
go back to reference Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL: Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 7:307–315, 1987PubMed Vergani D, Mieli-Vergani G, Mondelli M, Portmann B, Eddleston AL: Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver 7:307–315, 1987PubMed
28.
go back to reference Matsuo I, Ikuno N, Omagari K, Kinoshita H, Oka M, Yamaguchi H, Kohno S, Mackay IR: Autoimmune reactivity of sera to hepatocyte plasma membrane in type 1 autoimmune hepatitis. J Gastroenterol 35:226–234, 2000PubMedCrossRef Matsuo I, Ikuno N, Omagari K, Kinoshita H, Oka M, Yamaguchi H, Kohno S, Mackay IR: Autoimmune reactivity of sera to hepatocyte plasma membrane in type 1 autoimmune hepatitis. J Gastroenterol 35:226–234, 2000PubMedCrossRef
29.
go back to reference Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, McFarlane IG, Kiyosawa K, Furuta S, Freni MA, et al.: Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 107:799–804, 1994PubMed Treichel U, McFarlane BM, Seki T, Krawitt EL, Alessi N, Stickel F, McFarlane IG, Kiyosawa K, Furuta S, Freni MA, et al.: Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 107:799–804, 1994PubMed
30.
go back to reference Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, Lohse AW: Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355:1510–1515, 2000PubMedCrossRef Wies I, Brunner S, Henninger J, Herkel J, Kanzler S, Meyer zum Buschenfelde KH, Lohse AW: Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355:1510–1515, 2000PubMedCrossRef
31.
go back to reference Volkmann M, Martin L, Bäurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, Manns MP: Soluble liver antigen: Isolation of a 35 kD recombinant protein (SLA-P35) specifically recognizing sera from patients with autoimmune hepatitis type 3. Hepatology 33:591–596, 2001PubMedCrossRef Volkmann M, Martin L, Bäurle A, Heid H, Strassburg CP, Trautwein C, Fiehn W, Manns MP: Soluble liver antigen: Isolation of a 35 kD recombinant protein (SLA-P35) specifically recognizing sera from patients with autoimmune hepatitis type 3. Hepatology 33:591–596, 2001PubMedCrossRef
32.
go back to reference Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C: Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP (Ser) Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 121:364–374, 2000PubMedCrossRef Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C: Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP (Ser) Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 121:364–374, 2000PubMedCrossRef
33.
go back to reference Deocharan B, Qing X, Lichauco J, Putterman C: Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 168:3072–3078, 2002PubMed Deocharan B, Qing X, Lichauco J, Putterman C: Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 168:3072–3078, 2002PubMed
34.
go back to reference Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, Gilkeson GS, Bottinger EP, Putterman C: Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 54:2198–2210, 2006PubMedCrossRef Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, Gilkeson GS, Bottinger EP, Putterman C: Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 54:2198–2210, 2006PubMedCrossRef
Metadata
Title
Double Reactivity Against Actin and α-Actinin Defines a Severe Form of Autoimmune Hepatitis Type 1
Authors
GUÉGUEN PAUL
DALEKOS GEORGIOS
NOUSBAUM JEAN-BAPTISTE
ZACHOU KALLIOPI
PUTTERMAN CHAIM
YOUINOU PIERRE
RENAUDINEAU YVES
Publication date
01-11-2006
Published in
Journal of Clinical Immunology / Issue 6/2006
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-006-9045-z

Other articles of this Issue 6/2006

Journal of Clinical Immunology 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine